CSIMarket
 


Kymera Therapeutics Inc   (KYMR)
Other Ticker:  
 
 

KYMR's EPS from Cont. Operations Growth by Quarter and Year

Kymera Therapeutics Inc 's EPS from Cont. Operations results by quarter and year




KYMR EPS from Cont. Operations (in $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -0.79 -0.55 0.00
III Quarter September -0.90 -0.78 -0.29 0.00
II Quarter June -0.67 -0.71 0.25 0.00
I Quarter March -0.70 -0.56 -0.39 0.00
FY   -2.27 -2.84 -0.98 0.00



KYMR EPS from Cont. Operations third quarter 2022 Y/Y Growth Comment
Kymera Therapeutics Inc in the third quarter 2022 recorded EPS loss from Cont. Operations of $ -0.90 .

According to the results reported in the third quarter 2022, Kymera Therapeutics Inc achieved the best EPS from Cont. Operations growth in Biotechnology & Pharmaceuticals industry. While Kymera Therapeutics Inc ' s EPS from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2022.




KYMR EPS from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Kymera Therapeutics Inc 's third quarter 2022 EPS from Cont. Operations $ -0.90 KYMR's Income Statement
Kymera Therapeutics Inc 's third quarter 2021 EPS from Cont. Operations $ -0.78 Quarterly KYMR's Income Statement
New: More KYMR's historic EPS from Cont. Operations Growth >>


KYMR EPS from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




EPS from Cont. Operations third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
EPS from Cont. Operations third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

EPS from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Kymera Therapeutics Inc 's Q/Q EPS from Cont. Operations Growth


EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KYMR's III. Quarter Q/Q EPS from Cont. Operations Comment
Recent results of -0.90 by Kymera Therapeutics Inc come out even less good if you take a look at -0.67 in the second quarter.

Within Biotechnology & Pharmaceuticals industry Kymera Therapeutics Inc achieved highest sequential EPS from Cont. Operations growth. While Kymera Therapeutics Inc 's EPS from Cont. Operations growth quarter on quarter, overall rank is .


EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KYMR's III. Quarter Q/Q EPS from Cont. Operations Comment
Recent accomplishment of -0.90 by Kymera Therapeutics Inc appear even more unfavourable compare to the -0.67 in the previous quarter.

Within Biotechnology & Pharmaceuticals industry Kymera Therapeutics Inc achieved highest sequential EPS from Cont. Operations growth. While Kymera Therapeutics Inc 's EPS from Cont. Operations growth quarter on quarter, overall rank is .


Kymera Therapeutics Inc 's 12 Months EPS from Cont. Operations Growth Year on Year


EPS from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
Cumulative EPS from Cont. Operations 12 Months Ending $ -3.06 $ -2.94 $ -2.98 $ -2.84 $ -2.60
Y / Y EPS from Cont. Operations Growth (TTM) - - - - -
Year on Year EPS from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential EPS from Cont. Operations Change (TTM) - - - - -
Seq. EPS from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative EPS from Cont. Operations growth Comment
Kymera Therapeutics Inc ' has realized cumulative trailing twelve months EPS loss from Cont. Operations of $ -3 in the Sep 30 2023 period.
The business is getting worse as the cumulative EPS loss from Cont. Operations is becoming larger from $ -2.94 for the period from Jun 30 2023 to Jun 30 2022 and $ -2.11 for the twelve months ending in the quarter Jun 30 2022 Krishna Kapoor, Kapur  mentioned.

Kymera Therapeutics Inc achieved highest trailing twelve month year on year EPS from Cont. Operations growth. While overall EPS from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative EPS from Cont. Operations growth Comment
Kymera Therapeutics Inc ' has realized cumulative trailing twelve months EPS loss from Cont. Operations of $ -3 in the Sep 30 2023 period.
The results are getting worse as the cumulative EPS loss from Cont. Operations is getting bigger from $ -2.94 in the twelve months ending a quarter before and $ -2.11 from the TTM period ending Jun 30 2022.

Kymera Therapeutics Inc achieved highest trailing twelve month year on year EPS from Cont. Operations growth. While overall EPS from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other EPS from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry EPS from Cont. Operations Growth Trends and Statistics
Healthcare Sector EPS from Cont. Operations Growth Statistics
EPS from Cont. Operations Growth Trends for overall market
KYMR's EPS from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking EPS from Cont. Operations Growth
Lowest Ranking EPS from Cont. Operations Growth
EPS from Cont. Operations Growth for KYMR's Competitors
EPS from Cont. Operations Growth for Kymera Therapeutics Inc 's Suppliers
EPS from Cont. Operations Growth for KYMR's Customers

You may also want to know
KYMR's Annual Growth Rates KYMR's Profitability Ratios KYMR's Asset Turnover Ratio KYMR's Dividend Growth
KYMR's Roe KYMR's Valuation Ratios KYMR's Financial Strength Ratios KYMR's Dividend Payout Ratio
KYMR's Roa KYMR's Inventory Turnover Ratio KYMR's Growth Rates KYMR's Dividend Comparisons



Companies with similar EPS from Cont. Operations no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %EPS from Cont. Operations for the quarter ending Sep 30 2023
Bristol myers Squibb Company25.33%$ 25.333 
Gilead Sciences Inc 22.38%$ 22.378 
Progyny Inc 21.43%$ 21.429 
Dexcom Inc 19.23%$ 19.231 
Envoy Medical Inc 18.18%$ 18.182 
Neurocrine Biosciences Inc 18.06%$ 18.056 
Idexx Laboratories Inc17.51%$ 17.512 
Edwards Lifesciences Corporation14.55%$ 14.545 
Zoetis Inc 14.16%$ 14.159 
Ensign Group Inc11.76%$ 11.765 
Vertex Pharmaceuticals Inc10.47%$ 10.468 
Iqvia Holdings Inc 9.21%$ 9.211 
United Therapeutics Corporation8.56%$ 8.555 
Medpace Holdings Inc 7.98%$ 7.981 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com